AVANCES EN EL CONOCIMIENTO Y
MENEJO DE LAS DISLIPOPROTEINEMIAS
REFERENCIAS BIBLIOGRÁFICAS
1. Expert Panel on Detection, Evaluation and Treatment of High Blood Colesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Davignon J, Genest J Jr. Genetics of lipoprotein disorders. Endocrinol Metab Clin North America 1998; 27: 521-50.
3. Pando R, Garmendia F, Armas J, Torres W. Estudio de factores de riesgo en pacientes con enfermedad coronaria. XI Congreso Nacional y XXII Curso Internacional de Medicina Interna. Libro de Resúmenes. Lima, nov 2000: 111.
4. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-8.
5. Stamler J, Wentworth D, Neaton J, the MRFIT RESEARCH group. Is relationship between serum cholesterol and risk/of premature death from coronary heart disease continuous and
graded- JAMA 1986; 256: 2823-8.
6. Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994; 89: 2533-9.
7. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994; 89: 2525-32.
8. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-8.
9. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-83.
10. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. Circulation 1999; 100: 475-82.
11. Ginsberg HN. Hypertriglyceridemia: New insights and new approaches to pharmacology therapy. Am J Cardiol 2001; 87: 1174-80.
12. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-5.
13. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18B-25B.
14. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: 13B-17B.
15. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86:943-9.
16. Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 1998; 105: 58S-62S.
17. Garmendia F, Crispin S, Flores R y col. Lipemia postprandial en obesos. II Jornadas Científicas de Investigación en Salud. Facultad de Medicina, UNMSM, Libro de Resúmenes, Lima, 2000: 132.
18. Hardaman A, Lawrence JEM, Herd SL. Postprandial lipemia in endurance trained people during a short interruption to training. J Appl Physiol 1998; 84(6): 1895-901.
19. Weintraub MS, Rosen Y, Otto R, Eisenberg S, Breslow JL. Physical exercise conditioning in absence of weight loss reduce fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 1989; 79: 1007-14.
20. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention with Genfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
21. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by Ezetinibe in humans. Circulation 2002; 106: 1943.
22. The Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Lancet 1994; 344 (8934): 1383-9.
23. Garmendia F, Brown AS, Reiber I, Adams PC. Attaining Unites States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (The GOALLS study). Curr Med Res Opin 2000; 16(3): 208-19.
24. Furberg CD. Natural statins and stroke risk. Circulation 1999; 99: 185-8.
Bibliografía
|
